Q2 2025 13F Holders as of 6/30/2025
-
Type / Class
-
Equity / Common Stock, par value $0.0001 per share
-
Shares outstanding
-
19.3M
-
Number of holders
-
6
-
Total 13F shares, excl. options
-
2.44M
-
Shares change
-
-150M
-
Total reported value, excl. options
-
$21.6M
-
Value change
-
-$465M
-
Number of buys
-
1
-
Number of sells
-
-109
-
Price
-
$8.84
Significant Holders of Lyell Immunopharma, Inc. - Common Stock, par value $0.0001 per share (LYEL) as of Q2 2025
112 filings reported holding LYEL - Lyell Immunopharma, Inc. - Common Stock, par value $0.0001 per share as of Q2 2025.
Lyell Immunopharma, Inc. - Common Stock, par value $0.0001 per share (LYEL) has 6 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 2.44M shares
of 19.3M outstanding shares and own 12.66% of the company stock.
Largest 10 shareholders include MWG Management Ltd. (1.01M shares), Orland Properties Ltd (755K shares), Decheng Capital LLC (595K shares), JOHNSON & JOHNSON (41.2K shares), TAKEDA PHARMACEUTICAL CO LTD (41.2K shares), IFP Advisors, Inc (63 shares), SHELL ASSET MANAGEMENT CO (0 shares), Clarius Group, LLC (0 shares), PUBLIC EMPLOYEES RETIREMENT SYSTEM OF OHIO (0 shares), and US BANCORP \DE\ (0 shares).
This table shows the top 6 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.